Navigation Links
Dartmouth awarded lead role in NCI clinical trials network
Date:4/24/2014

(Lebanon, NH, 4/24/14) Dartmouth has been awarded one of 30 grants from the National Cancer Institute (NCI) to serve as a Lead Academic Participating Site in its new National Clinical Trials Network (NCTN). Award recipients are a select groups of investigators charged with distributing resources in a more effective way across fewer cooperative groups.

The NCTN grant system reflects recommendations from a 2010 Institute of Medicine Report. It streamlines operations to achieve four goals:

  • Faster design, launch, and completion of clinical trials

  • Optimal use of scientific innovations

  • Strategic prioritization of studies

  • Expanded participation of patients and physicians

Through a consolidation of operational resources, the NCTN untangles behind-the-scenes red tape by using:

  • A common IT data management systems

  • One Central Institutional Review Board

  • Integrated specimen banks and informatics systems

Everyonepatients, providers, and family memberswants to see faster access to new treatments for cancer, said Konstantin H. Dragnev, MD, principal investigator for the Dartmouth-Hitchcock Norris Cotton Cancer Center site. This new framework will cut the startup time for a clinical trial by 75 percent in some cases. It removes obstacles we used to face for reporting and oversight, so we can now offer therapeutic advances to patients sooner.

As a Lead Academic Participating Site, Norris Cotton Cancer Center will be charged with enhancing participation in NCI randomized phase three clinical trials, the gold standard in cancer research for establishing new treatments for a five year period. Participating sites provide scientific leadership in the development of clinical trials, while meeting performance benchmarks for quality clinical research. Dartmouth will oversee involvement and participation from affiliated patient enrollment settings in New Hampshire, Vermont, and other states.

As a group we can achieve more than we can individually, said Dragnev of the co-operative groups in the nationwide network. Urban and rural residents can participate in the same study, which expands our ability to include a more diverse population in an individual study. The Dartmouth-led affiliations also mean greater access to new therapies in relatively remote areas served in northern New England.

The new network represents an unmatched effort to integrate and streamline the process of cancer clinical trials research, said James Doroshow, MD, deputy director for clinical and translational research at NCI. The conduct of NCI-supported trials, which are publicly funded, involves a complex system of designing, reviewing, and initiating studies. The new NCTN replaces a structure that was more than 55 years old.

NCTN employs an inclusive process for generating studies and conducting clinical trials using broad representation from the oncology field, including academic researchers, as well as professional organizations, patients, and advocates.

The Network has combined smaller cooperative groups with specialized foci, such as, pediatric, breast/bowel, or gynecological cancers. These consolidated cooperative groups allow for closer communication and collaboration among researchers doing work in the same area. The newly announced Lead Academic Participating Sites will serve as common outlets for offering trials originating from any of these groups.

Norris Cotton Cancer Centers selection as a Lead Participating Site affirms our role as a national leader in cancer research, said Mark Israel, MD, director, Norris Cotton Cancer Center. We are among an elite group of investigators conducting nationally the highest caliber of scientific research.
'/>"/>

Contact: Donna Dubuc
Donna.M.Dubuc@Dartmouth.edu
603-653-3615
The Geisel School of Medicine at Dartmouth
Source:Eurekalert  

Related medicine news :

1. Dartmouth researchers develop new approach to chronic lymphocytic leukemia treatment
2. Dartmouth study provides first global evidence that foreign aid boosts public opinion
3. Dartmouth researcher finds novel genetic patterns that make us rethink biology and individuality
4. Clemson, Dartmouth use $1.5M grant to develop mobile health technology
5. Dartmouth researchers receive $5.9 million grant from NIH for lung research
6. Dartmouth researchers develop molecular switch that changes liquid crystal colors
7. Dartmouth researchers test safety of Nivolumab in kidney cancer
8. Leap in leukemia treatment reported by Dartmouth researchers
9. Dartmouth medical research closes in on new tuberculosis vaccine
10. Mayo Clinic, Dartmouth-Hitchcock announce collaboration
11. Dartmouth researchers investigate the cognitive effects of athlete head impacts
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Dartmouth awarded lead role in NCI clinical trials network
(Date:7/26/2017)... ... July 26, 2017 , ... ... cats has opened in Jupiter. The state of the art center will ... leading treatments with a goal of providing heart patients longer lives. , North ...
(Date:7/26/2017)... FL (PRWEB) , ... July 26, 2017 , ... ... nation’s leading innovative specialty pharmacies, has released an updated version of the HCV ... latest guidelines for treating chronic hepatitis C virus (HCV) infection. All of the ...
(Date:7/25/2017)... MOORE, OK (PRWEB) , ... July 25, 2017 ... ... are proud to announce the launch of their partnership to provide the ... is the first pharmacy-focused platform in the country with the ability to develop ...
(Date:7/25/2017)... ... July 25, 2017 , ... Dr. Gina ... Negrette has more than a decade of experience in psychiatry, treating clients in ... fighting addictions, eating disorders, psychotic and manic conditions, as well as those who ...
(Date:7/24/2017)... ... July 24, 2017 , ... Contact: ... Robins & Morton, Perkins Will, Newcomb & Boyd, Walter P Moore and ... new Destination Medical Building located at Mayo Clinic in Jacksonville, Florida. , ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... Minn. , July 20, 2017  Prime Therapeutics LLC ... Jonathan Gavras , M.D., following today,s Institute for Clinical and ... report on the effectiveness and value of abuse-deterrent formulations ... on the policy roundtable at the meeting. ... not a material cost benefit to the use of abuse-deterrent ...
(Date:7/14/2017)... -- It should come as no surprise to anyone that ... midst of a crippling opioid epidemic. According to the ... overdose deaths from opiate-based medications has quadrupled, Says, Dr. ... from 2001 to 2015". During this time, the prescription rate ... drawing a compelling link between prescription and eventual addiction. The ...
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
Breaking Medicine Technology: